Advertisement

Nipro Corporation Company Profile

23:26 EDT 19th June 2013 | BioPortfolio

Nipro Corporation (Tokyo Stock Exchange and Osaka Stock Exchange Ticker Code 8086), founded in 1954, is engaged directly and through its subsidiaries principally in the development, manufacture and sale of medical devices, pharmaceutical products and medical and glass products. Nipro’s medical device division is engaged in the manufacture and sale of medical devices and its related products, the development, manufacture and sale of cell culturing-related products, as well as the development and sale of diabetes-related products. Nipro also currently markets its own insulin pump through its U.S. diabetes division. Nipro’s pharmaceutical division is engaged in the research, manufacture and sale of pharmaceuticals, such as blood derivatives. The instrument division of Nipro manufactures and sells glass pipes and other glass products, including the inner bottles of thermos bottles. Nipro and its subsidiaries also sell medical device manufacturing equipment and conduct real estate leasing and non-life insurance agency businesses. For more information please visit www.nipro.co.jp.


News Articles [ 13 Associated News Articles listed on BioPortfolio]

Japan Nipro To Buy Two-Thirds Of Device-Maker Goodman For $36 Million

Japan's Nipro said it plans to buy a two-thirds stake in Goodman Co. Ltd, maker of medical equipment such as catheters, for $36 million and make it a subsidiary.

Nipro exit from troubled Bipha JV may smooth Mitsubishi Tanabe blood product rejig

The Japanese blood product operation Bipha will once again become a wholly owned subsidiary of Mitsubishi Tanabe Pharma (MTP) following a decision by long-time partner Nipro Corp to divest its inter...

Mitsubishi Tanabe to take full control of Bipha JV

Japanese drug major Mitsubishi Tanabe Pharma (TYO: 4508) has agreed to acquire the 49% holding (20,580 shares) held by fellow Japan based Nipro Corp in the blood product joint venture Bipha Corp, with...

Nipro Diagnostics, NextGen enter agreement for TRUEresult blood glucose monitoring system

NextGen Healthcare Information Systems, LLC, a wholly owned subsidiary of Quality Systems, Inc. and a leading provider of healthcare information systems and connectivity solutions, announced today it...

Mitsubishi Tanabe Pharma, Nipro deal

Nipro Diagnostics Introduces Extensive New Line of Ancillary Products for the Diabetes Category

Nipro Diagnostics, Inc. – a leading manufacturer and marketer of blood glucose monitoring products and diabetes management supplies – today announced that it has begun to ship...

Nipro Diagnostics Leverages Managed IT Services from JDL Technologies to Support Growth and Technological Innovation

FORT LAUDERDALE, Fla., April 23, 2013 /PRNewswire/ -- Nipro Diagnostics, Inc., a leading producer of diabetes management solutions used around the world and trusted by premier retail pharmacies t...

TRUEresult® Blood Glucose Meter Receives “Recommended” Rating From Leading National Consumer Publication/Testing Organization

The TRUEresult® blood glucose monitoring systems from Nipro Diagnostics, Inc. – a leading manufacturer and marketer of blood glucose monitoring products and diabetes management...

Drugs and Medications [0 Results]

None

PubMed Articles [ 1 Associated PubMed Articles listed on BioPortfolio]

Proteomic analysis of protein adsorption capacity of different haemodialysis membranes.

Protein-adsorptive properties are a key feature of membranes used for haemodialysis treatment. Protein adsorption is vital to the biocompatibility of a membrane material and influences membrane's perf...

Clinical Trials [ 1 Associated Clinical Trials listed on BioPortfolio]

Test of the Nipro ELISIO H Dialyzer in Different Dialysis Treatment Procedures

A current trend in dialysis membrane engineering is to maximize the permeability for larger low-molecular weight proteins while retaining albumin. Protein-leaking dialysis membranes do not...

Companies [ 2 Associated Companies listed on BioPortfolio]

Nipro Corporation

Nipro Corporation (Tokyo Stock Exchange and Osaka Stock Exchange Ticker Code 8086), founded in 1954, is engaged directly and through its subsidiaries principally in the developmen...

Nipro Diagnostics, Inc.

Based in Fort Lauderdale, Florida, Nipro Diagnostics, Inc. is a leading developer, manufacturer and marketer of diabetes management products. Nipro Diagnostics offers a portfolio...

More Information about "Nipro Corporation" on BioPortfolio

We have published hundreds of Nipro Corporation news stories on BioPortfolio along with dozens of Nipro Corporation Clinical Trials and PubMed Articles about Nipro Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Nipro Corporation Companies in our database. You can also find out about relevant Nipro Corporation Drugs and Medications on this site too.

Search BioPortfolio:
Advertisement

Corporate Database Quicklinks



Searches Linking to this Company Record

Advertisement